Description
Product details
ATOVASTRIN GOLD 10 Aspirin (75mg), Atorvastatin (10mg), Clopidogrel (75mg) ATOVASTRIN GOLD 10 represents a multifaceted approach to managing cardiovascular risk and preventing cardiovascular events, especially in individuals with established cardiovascular disease or at high risk for such conditions. Here's an overview of how these medications work together, along with considerations for their use. Aspirin Overview Classification: Antiplatelet agent Primary Use: Lowers the risk of heart attack and stroke by preventing blood clots. It inhibits the enzyme cyclooxygenase, which results in reduced synthesis of thromboxane A2, a molecule that encourages platelet aggregation. Benefits: Proven to reduce the risk of cardiovascular events in various populations, including those with a history of myocardial infarction, stroke, or those at high cardiovascular risk. Atorvastatin Overview Classification: Statin (HMG-CoA reductase inhibitor) Primary Use: Lowers LDL cholesterol (bad cholesterol) and triglycerides in the blood and slightly increases HDL cholesterol (good cholesterol). Mechanism of Action: Works by inhibiting the HMG-CoA reductase enzyme in the liver, leading to decreased cholesterol synthesis and increased clearance of LDL cholesterol. Benefits: Significantly reduces the risk of cardiovascular events by slowing the progression of atherosclerosis and promoting plaque stability. Clopidogrel Overview Classification: Antiplatelet agent Primary Use: Prevents platelets from clumping together to form clots, similar to aspirin but through a different mechanism—it irreversibly inhibits the ADP receptor on platelet cell membranes. Benefits: Especially used in patients intolerant to aspirin, with peripheral artery disease, after coronary stenting, or in combination with aspirin in certain high-risk patients to provide dual antiplatelet therapy. ATOVASTRIN GOLD 10 Rationale: This trio targets different aspects of cardiovascular risk: Aspirin and Clopidogrel: Provide dual antiplatelet effects, significantly reducing the risk of clot-related events such as heart attacks and strokes. Atorvastatin: Lowers cholesterol levels, addressing a key risk factor for atherosclerosis and subsequent cardiovascular events. Clinical Evidence: ATOVASTRIN GOLD 10 is often used in secondary prevention strategies for patients with coronary artery disease, particularly after acute coronary syndromes or coronary stenting, to reduce the risk of recurrent events. Considerations and Precautions: Bleeding Risk: The use of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel increases the risk of bleeding. The benefits of reducing thrombotic risk must be weighed against the increased bleeding risk, especially in certain populations. Monitoring: Patients may require monitoring for signs of bleeding, liver function tests, and lipid levels to adjust therapy as needed. Personalized Medicine: The decision to initiate this combination therapy should be based on a comprehensive assessment of the patient's cardiovascular risk, potential for adverse effects, and overall health status. For further information: Email: info@sterispharma.com / contact@sterispharma.com Call/WhatsApp: 7877551268, 7849827488 Buy Now: https://www.sterisonline.com/product/atovastrin-gold-10-133255
